Trial Profile
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Niacin/laropiprant (Primary) ; Niacin
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 16 Feb 2012 Actual patient number changed from 1153 to 1152 as reported by ClinicalTrials.gov.
- 16 Nov 2011 Primary endpoint 'Assessment-scale-scores' has been met, according to results presented at the 84th Annual Scientific Sessions of the American Heart Association.
- 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.